New cancer clinical trial: Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

Published on: March 01, 2018 at 12:00PM
Condition:   Nonsmall Cell Lung Cancer
Intervention:   Drug: AZD4205
Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Not yet recruiting
http://ift.tt/2CS4sbA